Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodones

Drug Metabolism and Disposition

Volumn 41, Issue 5, 2013, Pages 1060-1069

  Hassan, Hazem E ^a,c   Myers, Alan L ^a   Lee, Insong J ^a   Mason, Clifford W ^a   Wang, Duan ^a   Sinz, Michael W ^b   Wang, Hongbing ^a   Eddington, Natalie D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c Helwan   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CARRIER PROTEIN; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2B2; CYTOCHROME P450 3A1; DRUG METABOLITE; DRUG METABOLIZING ENZYME; MULTIDRUG RESISTANCE PROTEIN 1; NOROXYCODONE; OXYCODONE; OXYMORPHONE; PREGNANE X RECEPTOR; RECEPTOR PROTEIN; SLC22A8 PROTEIN; UNCLASSIFIED DRUG; XENOBIOTIC RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; GENE IDENTIFICATION; GENE TRANSLOCATION; GENETIC REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER; MALE; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REPEATED DRUG DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION; HUMANS; LIVER; MALE; OXYCODONE; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, DRUG; TRANSCRIPTIONAL ACTIVATION; XENOBIOTICS;

RATTUS;

EID: 84876747426     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.050401     Document Type: Article

References (58)

1. Ammon S, Mayer P, Riechert U, Tischmeyer H, and Höllt V (2003) Microarray analysis of genes expressed in the frontal cortex of rats chronically treated with morphine and after naloxone precipitated withdrawal. Brain Res Mol Brain Res 112:113-125.
2. Annereau JP, Szakács G, Tucker CJ, Arciello A, Cardarelli C, Collins J, Grissom S, Zeeberg BR, Reinhold W, and Weinstein JN, et al. (2004) Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol 66:1397-1405.
3. Aquilante CL, Letrent SP, Pollack GM, and Brouwer KL (2000) Increased brain P-glycoprotein in morphine tolerant rats. Life Sci 66:PL47-PL51.
4. Boelsterli UA, Lanzotti A, Göldlin C, and Oertle M (1992) Identification of cytochrome P-450IIB1 as a cocaine-bioactivating isoform in rat hepatic microsomes and in cultured rat hepatocytes. Drug Metab Dispos 20:96-101.
5. Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, and Murphy GP (1992) The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 70(1, Suppl) 291-301.
6. Burrows DL, Hagardorn AN, Harlan GC, Wallen ED, and Ferslew KE (2003) A fatal drug interaction between oxycodone and clonazepam. J Forensic Sci 48:683-686.
7. Calcagno A, D'Avolio A, Simiele M, Cusato J, Rostagno R, Libanore V, Baietto L, Siccardi M, Bonora S, and Di Perri G (2012) Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. Br J Clin Pharmacol 74:134-140.
8. Campbell SE and Febbraio MA (2002) Effect of the ovarian hormones on GLUT4 expression and contraction-stimulated glucose uptake. Am J Physiol Endocrinol Metab 282:E1139-E1146.
9. Chan S, Edwards SR, Wyse BD, and Smith MT (2008) Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. Clin Exp Pharmacol Physiol 35:295-302.
10. Choi YH, Lee U, Lee BK, and Lee MG (2010) Pharmacokinetic interaction between itraconazole and metformin in rats: Competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2. Br J Pharmacol 161:815-829.
11. Cone EJ, Fant RV, Rohay JM, Caplan YH, Ballina M, Reder RF, and Haddox JD (2004) Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions. J Anal Toxicol 28:616-624.
12. Cone EJ, Fant RV, Rohay JM, Caplan YH, Ballina M, Reder RF, Spyker D, and Haddox JD (2003) Oxycodone involvement in drug abuse deaths: A DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Anal Toxicol 27: 57-67, discussion 67.
13. Ekins S, Bugrim A, Brovold L, Kirillov E, Nikolsky Y, Rakhmatulin E, Sorokina S, Ryabov A, Serebryiskaya T, and Melnikov A, et al. (2006) Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms. Xenobiotica 36:877-901.
14. Emeterio EP, Tramullas M, and Hurlé MA (2006) Modulation of apoptosis in the mouse brain after morphine treatments and morphine withdrawal. J Neurosci Res 83:1352-1361.
15. Fang J, Quinones QJ, Holman TL, Morowitz MJ, Wang Q, Zhao H, Sivo F, Maris JM, and Wahl ML (2006) The H+-linked monocarboxylate transporter (MCT1/SLC16A1): A potential therapeutic target for high-risk neuroblastoma. Mol Pharmacol 70:2108-2115.
16. Gentleman RC, Carey VJ, Huber W, Irizarry RA, and Dudoit S (2005) Bioinformatics and Computational Biology Solutions Using R and Bioconductor, Springer, New York.
17. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
18. Guitart X and Nestler EJ (1989) Identification of morphine-and cyclic AMP-regulated phosphoproteins (MARPPs) in the locus coeruleus and other regions of rat brain: Regulation by acute and chronic morphine. J Neurosci 9:4371-4387.
19. Hassan HE, Myers AL, Lee IJ, Chen H, Coop A, and Eddington ND (2010) Regulation of gene expression in brain tissues of rats repeatedly treated by the highly abused opioid agonist, oxycodone: Microarray profiling and gene mapping analysis. Drug Metab Dispos 38: 157-167.
20. Hassan HE, Myers AL, Lee IJ, Coop A, and Eddington ND (2007) Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. J Pharm Sci 96:2494-2506.
21. Hays LR (2004) A profile of OxyContin addiction. J Addict Dis 23:1-9.
22. Heiskanen T, Olkkola KT, and Kalso E (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64:603-611.
23. Holtman JR, Jr and Wala EP (2006) Characterization of the antinociceptive effect of oxycodone in male and female rats. Pharmacol Biochem Behav 83:100-108.
24. Homayoun H, Khavandgar S, Mehr SE, Namiranian K, and Dehpour AR (2003) The effects of FK506 on the development and expression of morphine tolerance and dependence in mice. Behav Pharmacol 14:121-127.
25. Jover R, Ponsoda X, Gómez-Lechón J, and Castell JV (1993) Cocaine hepatotoxicity: Two different toxicity mechanisms for phenobarbital-induced and non-induced rat hepatocytes. Biochem Pharmacol 46:1967-1974.
26. Kalso E, Vainio A, Mattila MJ, Rosenberg PH, and Seppälä T (1990) Morphine and oxycodone in the management of cancer pain: Plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 67:322-328.
27. Kim RB (2002) Transporters and xenobiotic disposition. Toxicology 181-182:291-297.
28. Kim WY and Benet LZ (2004) P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res 21:1284-1293.
29. Kloss MW, Cavagnaro J, Rosen GM, and Rauckman EJ (1982) Involvement of FAD-containing monooxygenase in cocaine-induced hepatotoxicity. Toxicol Appl Pharmacol 64:88-93.
30. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
31. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, and Shen DD (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites. Clin Pharmacol Ther 79:461-479.
32. LeCluyse EL, Alexandre E, Hamilton GA, Viollon-Abadie C, Coon DJ, Jolley S, and Richert L (2005) Isolation and culture of primary human hepatocytes. Methods Mol Biol 290: 207-229.
33. Lee HK, Lewis LD, Tsongalis GJ, McMullin M, Schur BC, Wong SH, and Yeo KT (2006) Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism. Clin Chim Acta 367:196-200.
34. Li H, Chen T, Cottrell J, and Wang H (2009) Nuclear translocation of adenoviral-enhanced yellow fluorescent protein-tagged-human constitutive androstane receptor (hCAR): A novel tool for screening hCAR activators in human primary hepatocytes. Drug Metab Dispos 37: 1098-1106.
35. Li L, Hassan HE, Tolson AH, Ferguson SS, Eddington ND, and Wang H (2010) Differential activation of pregnane X receptor and constitutive androstane receptor by buprenorphine in primary human hepatocytes and HepG2 cells. J Pharmacol Exp Ther 335:562-571.
36. Li L, Sinz MW, Zimmermann K, and Wang H (2012) An insulin-like growth factor 1 receptor inhibitor induces CYP3A4 expression through a pregnane X receptor-independent, noncanonical constitutive androstane receptor-related mechanism. J Pharmacol Exp Ther 340: 688-697.
37. Lin JH (2003) Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 55:53-81.
38. McClung CA, Nestler EJ, and Zachariou V (2005) Regulation of gene expression by chronic morphine and morphine withdrawal in the locus ceruleus and ventral tegmental area. J Neurosci 25:6005-6015.
39. Myers AL, Hassan HE, Lee IJ, and Eddington ND (2010) Repeated administration of oxycodone modifies the gene expression of several drug metabolising enzymes in the hepatic tissue of male Sprague-Dawley rats, including glutathione S-transferase A-5 (rGSTA5) and CYP3A2. J Pharm Pharmacol 62:189-196.
40. Nakazawa Y, Okura T, Shimomura K, Terasaki T, and Deguchi Y (2010) Drug-drug interaction between oxycodone and adjuvant analgesics in blood-brain barrier transport and antinociceptive effect. J Pharm Sci 99:467-474.
41. Nielsen CK, Ross FB, and Smith MT (2000) Incomplete, asymmetric, and route-dependent crosstolerance between oxycodone and morphine in the Dark Agouti rat. J Pharmacol Exp Ther 295: 91-99.
42. Nieminen TH, Hagelberg NM, Saari TI, Neuvonen M, Laine K, Neuvonen PJ, and Olkkola KT (2010) St John's wort greatly reduces the concentrations of oral oxycodone. Eur J Pain 14: 854-859.
43. Nieminen TH, Hagelberg NM, Saari TI, Pertovaara A, Neuvonen M, Laine K, Neuvonen PJ, and Olkkola KT (2009) Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 110:1371-1378.
44. Pöyhiä R and Kalso EA (1992) Antinociceptive effects and central nervous system depression caused by oxycodone and morphine in rats. Pharmacol Toxicol 70:125-130.
45. Shippy R, Sendera TJ, Lockner R, Palaniappan C, Kaysser-Kranich T, Watts G, and Alsobrook J (2004) Performance evaluation of commercial short-oligonucleotide microarrays and the impact of noise in making cross-platform correlations. BMC Genomics 5:61.
46. Tirona RG and Kim RB (2005) Nuclear receptors and drug disposition gene regulation. J Pharm Sci 94:1169-1186.
47. Tolson AH, Li H, Eddington ND, and Wang H (2009) Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor. Drug Metab Dispos 37:1887-1894.
48. Tono T, Iwazawa T, Matsui S, Yano H, Kimura Y, Kanoh T, Ohnishi T, Nakano Y, Okamura J, and Monden T (2004) Hepatic arterial infusion of paclitaxel for liver metastasis from gastric cancer. Cancer Invest 22:550-554.
49. van der Hoeven TA and Coon MJ (1974) Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem 249:6302-6310.
50. Vanwert AL, Bailey RM, and Sweet DH (2007) Organic anion transporter 3 (Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G. Am J Physiol Renal Physiol 293:F1332-F1341.
51. VanWert AL and Sweet DH (2008) Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: A gender specific impact of reduced folates. Pharm Res 25: 453-462.
52. Wang H, Faucette SR, Gilbert D, Jolley SL, Sueyoshi T, Negishi M, and LeCluyse EL (2003) Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes. Drug Metab Dispos 31:620-630.
53. Waxman DJ (1984) Rat hepatic cytochrome P-450 isoenzyme 2c. Identification as a malespecific, developmentally induced steroid 16 alpha-hydroxylase and comparison to a femalespecific cytochrome P-450 isoenzyme. J Biol Chem 259:15481-15490.
54. Weinstein SH and Gaylord JC (1979) Determination of oxycodone in plasma and identification of a major metabolite. J Pharm Sci 68:527-528.
55. Wu Z, Irizarry RA, Gentleman R, Martine-Murillo F, and Spencer F (2004) A modelbased background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 99: 909-917.
56. Yue J, Khokhar J, Miksys S, and Tyndale RF (2009) Differential induction of ethanolmetabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake. Eur J Pharmacol 609:88-95.
57. Zhu Z, Kim S, Chen T, Lin JH, Bell A, Bryson J, Dubaquie Y, Yan N, Yanchunas J, and Xie D, et al. (2004) Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J Biomol Screen 9:533-540.
58. Zhu Z, Puglisi J, Connors D, Stewart J, Herbst J, Marino A, Sinz M, O'Connell J, Banks M, and Dickinson K, et al. (2007) Use of cryopreserved transiently transfected cells in high-throughput pregnane X receptor transactivation assay. J Biomol Screen 12:248-254.